...
首页> 外文期刊>Expert Review of Molecular Diagnostics >Discovery of prostate cancer biomarkers by microarray gene expression profiling.
【24h】

Discovery of prostate cancer biomarkers by microarray gene expression profiling.

机译:通过微阵列基因表达谱发现前列腺癌生物标志物。

获取原文
获取原文并翻译 | 示例

摘要

Prostate cancer is the most commonly diagnosed malignancy in males in the Western world. This review focuses on advances in biomarker discovery for prostate cancer by microarray profiling of mRNA and microRNA expression. Novel biomarkers are strongly needed to enable more accurate detection of prostate cancer, improve prediction of tumor aggressiveness and facilitate discovery of new therapeutic targets for tailored medicine. Promising molecular markers identified from gene expression profiling studies include AMACR, EZH2, TMPRSS2-ERG, miR-221 and miR-141, which are described in more detail. In addition, a compilation of prognostic gene expression signatures for prediction of prostate cancer patient outcome is provided, and their possible clinical utility is discussed. Furthermore, limitations in the application of microarray-based expression profiling for identification of prostate cancer biomarkers are addressed.
机译:前列腺癌是西方世界男性中最常见的恶性肿瘤。这篇综述着重于通过mRNA和microRNA表达的微阵列分析发现前列腺癌生物标志物的进展。迫切需要新型生物标志物,以能够更准确地检测前列腺癌,改善对肿瘤侵袭性的预测并促进发现针对定制药物的新治疗靶标。从基因表达谱研究中鉴定出的有前途的分子标记包括AMACR,EZH2,TMPRSS2-ERG,miR-221和miR-141,将对其进行详细说明。另外,提供了用于预测前列腺癌患者预后的预后基因表达签名的汇编,并讨论了其可能的临床实用性。此外,解决了基于微阵列的表达谱在鉴定前列腺癌生物标记物中的应用的局限性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号